A recent FDA-led pilot study evaluating kratom’s safety revealed the botanical was “well tolerated” in single doses up to 12 grams under clinical conditions. The trial, involving 40 healthy participants with no substance abuse history, tested escalating doses of encapsulated kratom leaf powder. While higher doses (8–12 grams) caused transient nausea—attributed to the bulk of ingesting up to 24 capsules—researchers observed no severe adverse effects beyond minor pupil dilation.
Christopher McCurdy, a University of Florida medicinal chemist and study co-author, noted the findings open doors for further research into kratom’s therapeutic potential, particularly for pain management and opioid withdrawal. The study used rigorously tested kratom from Super Speciosa, a supplier advocating for industry regulation and standardized manufacturing practices.
FDA emphasized the need for additional studies to assess risks linked to commercial kratom products, including extracts with concentrated alkaloids. Advocates hope the results prompt balanced oversight rather than outright bans. For full details, read the original SupplySide SJ report.